Fidelity Investments’s KalVista Pharmaceuticals KALV Stock Holding History

Fidelity Investments’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.78M	Buy	187,848 +76,041	+68%	+$1.23M	﹤0.01%	2404
2025 Q4	$1.81M	Buy	111,807 +19,439	+21%	+$257K	﹤0.01%	2653
2025 Q3	$1.13M	Sell	92,368 -41,198	-31%	-$569K	﹤0.01%	2755
2025 Q2	$1.51M	Buy	133,566 +50,670	+61%	+$619K	﹤0.01%	2585
2025 Q1	$957K	Buy	82,896 +891	+1%	+$9.09K	﹤0.01%	2693
2024 Q4	$695K	Buy	82,005 +15,582	+23%	+$161K	﹤0.01%	2796
2024 Q3	$769K	Buy	66,423 +12,397	+23%	+$156K	﹤0.01%	2689
2024 Q2	$636K	Buy	54,026 +3,119	+6%	+$36.4K	﹤0.01%	2650
2024 Q1	$604K	Sell	50,907 -63	-0.1%	-$840	﹤0.01%	2660
2023 Q4	$624K	Sell	50,970 -6,596	-11%	-$60K	﹤0.01%	2610
2023 Q3	$554K	Sell	57,566 -13,299	-19%	-$136K	﹤0.01%	2602
2023 Q2	$638K	Sell	70,865 -30	-0%	-$277	﹤0.01%	2584
2023 Q1	$557K	Sell	70,895 -1,240,107	-95%	-$9.25M	﹤0.01%	2656
2022 Q4	$8.86M	Buy	1,311,002 +152,617	+13%	+$817K	﹤0.01%	1940
2022 Q3	$16.8M	Buy	1,158,385 +25,943	+2%	+$363K	﹤0.01%	1668
2022 Q2	$11.1M	Buy	1,132,442 +307,092	+37%	+$3.39M	﹤0.01%	1927
2022 Q1	$12.2M	Buy	825,350 +38,130	+5%	+$548K	﹤0.01%	2035
2021 Q4	$10.4M	Sell	787,220 -173,741	-18%	-$2.77M	﹤0.01%	2098
2021 Q3	$16.8M	Sell	960,961 -127,829	-12%	-$2.59M	﹤0.01%	1922
2021 Q2	$26.1M	Sell	1,088,790 -259,180	-19%	-$6.78M	﹤0.01%	1729
2021 Q1	$34.6M	Sell	1,347,970 -292,308	-18%	-$7.68M	﹤0.01%	1549
2020 Q4	$31.1M	Sell	1,640,278 -101,335	-6%	-$1.74M	﹤0.01%	1518
2020 Q3	$21.9M	Sell	1,741,613 -22,243	-1%	-$278K	﹤0.01%	1523
2020 Q2	$21.3M	Sell	1,763,856 -26,935	-2%	-$286K	﹤0.01%	1524
2020 Q1	$13.7M	Buy	1,790,791 +123,813	+7%	+$1.67M	﹤0.01%	1571
2019 Q4	$29.7M	Buy	1,666,978 +742,033	+80%	+$9.68M	﹤0.01%	1440
2019 Q3	$10.7M	Sell	924,945 -51,535	-5%	-$833K	﹤0.01%	1799
2019 Q2	$21.6M	Buy	976,480 +241,466	+33%	+$5.66M	﹤0.01%	1597
2019 Q1	$21M	Buy	+735,014	New	+$15.9M	﹤0.01%	1588
2016 Q2	–	Sell	-139,432	Closed	-$1.26M	–	2672
2016 Q1	$1.26M	Sell	139,432 -100,936	-42%	-$1.81M	﹤0.01%	2451
2015 Q4	$12.2M	Buy	240,368 +2,765	+1%	+$145K	﹤0.01%	1910
2015 Q3	$11.9M	Buy	237,603 +1,408	+0.6%	+$120K	﹤0.01%	1884
2015 Q2	$23.6M	Buy	+236,195	New	+$23.4M	﹤0.01%	1664

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments's KALV Position: Q1 2026 in Review

Fidelity Investments increased its KalVista Pharmaceuticals (KALV) stake by 68% in Q1 2026, buying an estimated $1.23M and bringing the position to 187,848 shares worth $3.78M. The position accounts for ﹤0.01% of the portfolio, ranked #2404.

Fidelity Investments first reported a position in KALV in Q2 2015 and has held it in 33 quarters since. The position peaked at $34.6M in Q1 2021. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Fidelity Investments held 187,848 shares of KalVista Pharmaceuticals worth $3.78M as of Q1 2026.
Fidelity Investments bought 76,041 KalVista Pharmaceuticals shares in Q1 2026, an estimated $1.23M.
KalVista Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2404 holding.
Fidelity Investments first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 33 quarters since.
Fidelity Investments's KalVista Pharmaceuticals position peaked at $34.6M in Q1 2021.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.